ImmunityBio Awarded Seminal Patent on Natural Killer Cells

ImmunityBio, Inc. has been granted a US patent for a novel natural killer cell therapy composition and method for treating cancer that combines the company’s genetically modified NK-92 cells with CD16 receptors to enhance binding and activity of monoclonal antibodies.